Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global osteoporosis biosimilars market was valued at USD 1.71 billion in 2024 and is projected to reach USD 2.2 billion by 2031, exhibiting a CAGR of 3.8% during the forecast period.
Osteoporosis biosimilars are a class of follow-up biologic products that are equivalent to approved osteoporosis biologic drugs in quality, safety and efficacy. These products undergo rigorous regulatory review and must demonstrate no significant differences in key properties from the original drug to gain approval. This regulatory pathway ensures patient safety while increasing treatment accessibility through lower costs compared to originator products.
The market's growth is primarily driven by the increasing global prevalence of osteoporosis, particularly among aging populations. According to the International Osteoporosis Foundation, osteoporosis affects over 200 million people worldwide, with approximately 8.9 million fractures occurring annually due to the condition. Additionally, the expiration of patents for major biologic osteoporosis treatments has created opportunities for biosimilar development, while healthcare cost containment pressures in major markets are pushing providers toward more affordable treatment options.
Regionally, North America currently holds the largest market share at approximately 45%, followed by Europe at 35%, due to well-established regulatory pathways for biosimilars and higher treatment adoption rates. However, Asia-Pacific is expected to show the highest growth rate during the forecast period, driven by increasing healthcare access and growing awareness of osteoporosis treatment in countries like China and India.
The market faces several challenges, including complex manufacturing requirements for biosimilars, stringent regulatory requirements across different regions, and the need for extensive clinical data to demonstrate equivalence. However, the significant cost savings offered by biosimilars - typically 20-35% lower than originator products - continues to drive market expansion, particularly in price-sensitive markets and healthcare systems with budget constraints.
Growing Geriatric Population Driving Demand
The increasing global population of adults over 65, who are most susceptible to osteoporosis, is creating sustained demand for bone health treatments. This demographic shift is particularly pronounced in developed regions where healthcare access is more widespread.
Rising Treatment Adoption in Emerging Markets
As healthcare infrastructure improves in developing nations, more patients are gaining access to advanced osteoporosis treatments. The growing middle class in countries like India and Brazil is increasingly seeking preventive care and early intervention for bone health issues.
Market research indicates biosimilar adoption could reduce treatment costs by up to 40% compared to originator biologics, making treatment more accessible globally
Healthcare providers are increasingly recognizing the cost-effectiveness of biosimilars, with many hospital systems establishing formal protocols for biosimilar utilization in osteoporosis treatment pathways.
MARKET CHALLENGES
Regulatory Hurdles and Approval Processes
Navigating the complex regulatory landscape for biosimilars remains challenging, with different regions having varying requirements for demonstrating therapeutic equivalence. The stringent documentation and testing requirements can delay market entry by 12-18 months in some jurisdictions.
Other Challenges
Manufacturing Complexity and Scale-Up Challenges
Producing consistent, high-quality biosimilars requires sophisticated manufacturing processes that can be difficult to scale. Maintaining batch-to-batch consistency while scaling production to meet growing demand presents significant technical and operational challenges for manufacturers.
Patent Cliffs and Originator Strategies
Originator companies are employing aggressive patent strategies and lifecycle management techniques that can delay biosimilar market entry. The increasing complexity of biologics patents creates additional hurdles for biosimilar manufacturers seeking market entry.
Untapped Emerging Markets with Growing Healthcare Access
Rising healthcare investment in Southeast Asia, Latin America, and parts of Africa is creating new markets for osteoporosis treatments. The growing middle class in these regions is increasingly able to access advanced treatments, with biosimilars offering a more affordable entry point to biological therapies.
Digital Health Integration and Remote Monitoring
The integration of digital health platforms with osteoporosis treatment is creating new opportunities for patient monitoring and adherence support. Remote monitoring technologies combined with biosimilar treatments could revolutionize osteoporosis management in underserved regions, potentially reaching an additional 15-20 million patients by 2030.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
250g/mL is anticipated to be a leading segment due to its direct equivalence to established originator formulations, which facilitates smoother adoption by healthcare providers and regulatory bodies. This concentration is particularly prominent for subcutaneous administration, aligning with treatment protocols that prioritize ease of use for patients and clinical staff. The familiarity and demonstrated clinical profile of this specific strength provide a significant advantage in market penetration and physician confidence. |
| By Application |
|
Hospital settings are the leading application segment, as they are the primary centers for administering injectable biologic treatments to patients with moderate to severe osteoporosis. Hospitals possess the necessary infrastructure for drug storage, handling, and administration, and they manage complex patient cases requiring comprehensive care. The trend towards value-based healthcare and bulk purchasing agreements further solidifies the hospital segment's dominance, as these institutions are key drivers for adopting cost-effective biosimilar options to manage budgets without compromising patient outcomes. |
| By End User |
|
Public Healthcare Providers are expected to be the leading end-user segment, driven by their focus on cost containment while managing large patient populations with chronic conditions like osteoporosis. These providers are under significant pressure to optimize pharmaceutical budgets, making highly similar yet more affordable biosimilars an attractive proposition. The adoption by public systems often sets a precedent for broader market acceptance and can influence prescribing patterns across both public and private sectors, reinforcing this segment's prominence. |
| By Drug Class |
|
RANK Ligand Inhibitor Biosimilars are projected to lead this segment, reflecting the strong clinical demand for effective antiresorptive therapies. Biosimilars targeting this mechanism of action benefit from the established efficacy and safety profile of their reference products in reducing fracture risk. The high unmet need for long-term management of bone density loss, combined with the potential for significant cost savings, positions this class as a foundational element in the osteoporosis biosimilars landscape, with robust growth potential. |
| By Distribution Channel |
|
Direct Tender/Sales is the leading distribution channel, primarily because biosimilar procurement for chronic diseases like osteoporosis is increasingly managed through large-scale tendering processes by hospital networks and government health agencies. This channel allows for negotiated pricing and ensures a stable supply chain for high-volume users. The direct relationship between manufacturers and large institutional buyers facilitates the implementation of preferred drug policies and educational initiatives, which are crucial for the successful uptake of biosimilars in a competitive market. |
The Market is Characterized by a Mix of Established Pharmaceutical Giants and Specialized Biosimilar Developers
The global osteoporosis biosimilars market features a competitive landscape with a number of key players vying for market share. The market structure is fragmented, with the top five players collectively accounting for a significant portion of the global revenue as of 2024. Leading manufacturers include global pharmaceutical companies with extensive biosimilar portfolios, such as Novartis AG (through its Sandoz division) and Teva Pharmaceuticals, Inc., which leverage their vast distribution networks and regulatory expertise. These established players compete alongside specialized biotechnology and pharmaceutical firms that focus on the development and commercialization of biosimilar therapeutics, driving competition through cost-effective production and strategic market entries.
Beyond the major global entities, numerous other companies hold significant niches within the osteoporosis biosimilars space. These players often focus on specific regional markets or particular product formulations. Companies such as Intas Pharmaceuticals Ltd. and Cadila Pharmaceuticals (Zydus Cadila) have a strong presence in emerging markets, while others like STADA Arzneimittel AG and Alvogen, Inc. are key participants in the European and American markets. Several Asia-Pacific based manufacturers, including Sun Pharma ANZ Pty Ltd, Mochida Pharmaceutical Co., Ltd, and a growing number of Chinese biotech firms, are increasingly important, contributing to the global supply and intensifying competition through aggressive pricing strategies and regional expansion.
List of Key Osteoporosis Biosimilars Companies ProfiledBiosidus SA
Gedeon Richter Australia Pty Ltd
Mochida Pharmaceutical Co., Ltd
Alvogen, Inc
Theramex Ireland Ltd
Sun Pharma ANZ Pty Ltd
Strides Pharma
Apotex Corp
Novartis AG
Cipla Ltd
Qilu Pharmaceutical Co., Ltd
The global Osteoporosis Biosimilars market is on a trajectory of consistent growth, with its value projected to increase from US$ 1710 million in 2024 to US$ 2205 million by 2031, representing a compound annual growth rate (CAGR) of 3.8%. This expansion is primarily fueled by the fundamental value proposition of biosimilars: providing high-quality, safe, and effective therapeutic alternatives to original biologic drugs at a lower cost. This cost-advantage significantly enhances treatment accessibility for a larger patient population suffering from osteoporosis, a chronic condition requiring long-term management. The rigorous regulatory pathway for biosimilar approval ensures that these products demonstrate no clinically meaningful differences from their reference products, building confidence among physicians and patients and facilitating their integration into standard care protocols.
Other TrendsDiverse Product Landscape and Regional Market Dynamics
The market is characterized by a diverse range of product types, including formulations such as 250g/mL, 60 mg/mL, and 70 mg/mL, catering to different treatment regimens. Geographically, the market landscape is varied. While the United States represents a major established market, China is identified as a high-growth region poised for significant expansion. The competitive environment is fragmented, featuring a mix of established pharmaceutical companies and specialized biosimilar developers. Key players such as Biosidus SA, Cadila Pharmaceuticals, STADA Arzneimittel AG, and Novartis AG, among others, compete on the basis of manufacturing capability, regulatory expertise, and market reach. In 2024, the top five manufacturers collectively held a substantial share of the global revenue.
Application-wise, hospitals and clinics are the primary distribution channels for osteoporosis biosimilars. The use of these products in hospital settings is significant due to the administration of certain osteoporosis treatments that require clinical supervision. The "Others" application segment, which may include specialized infusion centers or retail pharmacies for oral formulations, also contributes to market volume. The ongoing analysis of sales and revenue data across these segments helps stakeholders identify high-growth opportunities. The market's evolution is closely tied to healthcare policies, reimbursement structures, and the continued demonstration of real-world evidence supporting the long-term efficacy and safety of biosimilars in managing osteoporosis.
Regional Analysis: Osteoporosis Biosimilars MarketEurope
Europe represents a highly developed and consolidated market for osteoporosis biosimilars, underpinned by the centralized approval mechanism of the European Medicines Agency (EMA). The region benefits from strong national healthcare systems in countries like Germany, France, and the UK, which actively promote biosimilar use through tendering processes and prescribing quotas to achieve cost savings. Physician acceptance is generally high, supported by a long history of using biosimilars in other therapeutic areas. However, market dynamics can vary significantly between Western and Eastern European countries due to differences in economic development and healthcare funding. Pan-European initiatives aimed at harmonizing prescribing practices are helping to drive consistent uptake across the region, making it a key strategic battleground for biosimilar manufacturers.
Asia-Pacific
The Asia-Pacific region is the fastest-growing market for osteoporosis biosimilars, fueled by a massive and aging population, rising healthcare expenditure, and increasing awareness of bone health. Japan and South Korea lead the region with advanced regulatory systems and early adoption of biosimilars, while China's market is expanding rapidly due to regulatory reforms and government support for local biomanufacturing. Countries like Australia have robust pricing and reimbursement policies that favor biosimilar entry. The region presents a diverse landscape, with varying levels of healthcare infrastructure and patient access. Local manufacturing is becoming increasingly important, creating opportunities for regional players to compete with global pharmaceutical giants.
South America
The osteoporosis biosimilars market in South America is emerging, with growth primarily driven by Brazil and Argentina. These countries are developing more structured regulatory pathways for biosimilars, though approval processes can be slower and more variable than in North America or Europe. Market access is often challenged by economic volatility and budget constraints within public healthcare systems. Despite these hurdles, the significant unmet medical need due to a growing elderly population creates a compelling case for market development. Biosimilars are viewed as a crucial tool for improving treatment accessibility, prompting increased interest from both multinational and local companies.
Middle East & Africa
This region presents a nascent but promising market for osteoporosis biosimilars, characterized by stark contrasts between the affluent Gulf Cooperation Council (GCC) countries and other developing nations. The GCC markets, such as Saudi Arabia and the UAE, have well-funded healthcare systems and are increasingly adopting international regulatory standards, facilitating biosimilar uptake. In contrast, much of Africa faces significant challenges related to healthcare infrastructure, affordability, and regulatory harmonization. The primary growth driver is the rising prevalence of osteoporosis linked to changing lifestyles and demographics. Market development is gradual, with potential for significant expansion as healthcare systems mature and awareness increases.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
<>Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global osteoporosis biosimilars market was valued at USD 1.71 billion in 2024 and is expected to reach USD 2.2 billion by 2031.
Which key companies operate in Global Osteoporosis Biosimilars Market?
-> Key players include Biosidus SA, Cadila Pharmaceuticals, Gedeon Richter Australia Pty Ltd, Mochida Pharmaceutical Co., Ltd, STADA Arzneimittel AG, and Alvogen, Inc, among others.
-> Key growth drivers include increasing global prevalence of osteoporosis, aging populations, and healthcare cost containment pressures.
-> North America holds the largest market share, while Asia-Pacific shows the highest growth rate.
-> Emerging trends include biosimilar development following patent expirations and expanding treatment accessibility.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates